摘要:
Disclosed is a novel peptide having one of the formulae: ##STR1## (A and B are the amino acids: wherein if A is D- or L-Pro, B is Hat or Cit;if A is D-Pro, B is D-Arg, andif B is D- or L-Arg, A is Sat, Pip, Aze or Arg)Asn-A-L- (D-)Pro-Arg- (Gly)n (A is Set, Thr or Ala, n is 1 or 0)A-Ser-Pip-Arg (A is Pro-Asn-, Asn- or Pro-) ##STR2## (A is cyclopentylcarbonyl, Pro or pGlu; B is Gly or .beta.-Ala, W is a hydrogen atom or a group having the formula:or a peptide having the formula: ##STR3## wherein A and B have the same meanings as mentioned above, respectively pGlu-Asn-Ser-A-B-(Gly)n (A is Aze, D- or L-Pro, Pip or Sat, B is D- or L-Arg, Cit, Hat, Lys or Orn, n is 1 or 0) andPro- (Ash)m-Set-L- (D-)Pro-Arg- (Gly) n (m and n are independently 0 or 1)their functional derivatives, and pharmaceutically acceptable salts thereof.
摘要:
Disclosed is a novel peptide having one of the formulae: ##STR1## (A and B are the amino acids: wherein if A is D- or L-Pro, B is Har or Cit;if A is D-Pro, B is D-Arg, andif B is D- or L-Arg, A is Sar, Pip, Aze or Arg)Asn-A-L-(D-)Pro-Arg-(Gly).sub.n(A is Ser, Thr or Ala, n is 1 or 0)A-Ser-Pip-Arg(A is Pro-Asn-, Asn- or Pro-) ##STR2## (A is cyclopentylcarbonyl, Pro or pGlu; B is Gly or .beta.-Ala, W is a hydrogen atom or a group having the formula: or a peptide having the formula: ##STR3## wherein A and B have the same meanings as mentioned above, respectivelypGlu-Asn-Ser-A-B-(Gly).sub.n(A is Aze, D- or L-Pro, Pip or Sar, B is D- or L-Arg, Cit, Har, Lys or Orn, n is 1 or 0) andPro-(Asn).sub.m -Ser-L-(D-)Pro-Arg-(Gly).sub.n(m and n are independently 0 or 1)their functional derivatives, and pharmaceutically acceptable salts thereof.
摘要:
A novel peptide derivative having the formula: ##STR1## wherein A between Pro and Q.sup.2 is Arg or Lys: Q.sup.1 is pGlu or H; Q.sup.2 is --Gly--OH or OH; Y.sup.1 is H or --CO--T and Y.sup.2 is OH or T; wherein T is a thiamine derivative group is disclosed. The peptide derivative shows a remarkable nootropic effect.
摘要:
A peptide having one of the following formulae (I), (II), (III) and (IV): ##STR1## or its functional derivatives, and a pharmaceutically acceptable salt thereof are disclosed. These peptides have a nootropic effect and are effective as antidementia agents.
摘要:
Disclosed are new alkylenediamine derivatives of the following formula which are effective for treatment of dysuria are disclosed: ##STR1## wherein R.sup.1 is hydrogen, alkyl, or a substituted or unsubstituted phenyl, naphthyl or aromatic heterocyclic group; R.sup.2 is a substituted or unsubstituted phenyl, naphthyl or aromatic heterocyclic group; R.sup.3 and R.sup.4 represent hydrogen, alkyl, aralkyl or aryl; or R.sup.3 and R.sup.4 are combined to form one of substituted or unsubstituted 5- to 7-membered heterocyclic groups; X is oxygen, sulfur or imino; Y is oxygen or sulfur; Z is --CH.sub.2 --, --CO-- or --CS--; m is an integer of 0-4; n is an integer of 0-4; r is 0 or 1; and p and q represent an integer of 0-5 provided that p plus q is 1-5.
摘要:
A process for protection of brain cells which comprises orally or parenterally administering into a man suffering from ischemia or being susceptible to ischemia a 1,3-oxazolidin-2-one derivative having the formula: ##STR1## wherein R is a straight or branched chain alkyl having 3-8 carbon atoms, X is hydrogen, halogen, a lower alkyl or alkoxy, and n is 4, 5 or 6. Representative examples of the active component are (4S,5R)-4-(2-methylpropyl)-5-phenyl-3-(3-piperidinopropyl)-1,3-oxazolidin-2-o ne and (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)-propyl]-5-phenyl-1,3-oxazolidin-2-one.
摘要:
Tertiary phosphine dichlorides are non-catalytically produced by directly reacting chlorine and carbon monoxide with a tertiary phosphine oxide preferably in a halogenated hydrocarbon solvent at a temperature of from -20.degree. to 100.degree. C.
摘要:
Disclosed is a process for catalytically producing phosgene in a high yield in a solvent. In this process, carbon monoxide gas is brought into contact with a solution containing chlorine and with a catalyst consisting of at least one phosphine chloride compound, so as to cause the carbon monoxide to react with the chlorine. The phosphine chloride catalyst compound can be selected from substituted and unsubstituted trialkylphosphine dichlorides, substituted and unsubstituted tetraalkyldiphosphine tetrachlorides, substituted and unsubstituted alkylphosphorane dichlorides, and substituted and unsubstituted alkylene-bis(alkylphosphine) tetrachlorides.
摘要:
Novel alkylenediamine derivatives effectively employable glutamate blockers have the formula (I) or (II): ##STR1## wherein each of R.sup.1 and R.sup.6 is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aryl group, or an aralkyl group; each of R.sup.2 and R.sup.7 is an aliphatic hydrocarbon group, an alkoxy group, an aliphatic hydrocarbon group containing an ester bonding, an aliphatic hydrocarbon group containing an ether bonding, or an aryloxy group; each of R.sup.3, R.sup.4, R.sup.5 R.sup.8, R.sup.9 and R.sup.10 is hydrogen, an alkyl group, an alkoxy group, an acyloxy group, an aryl group, an aralkyl group, hydroxyl, a hydroxylalkyl group, halogen, nitrile, nitro, amino, carbamoyl or alkoxycarbonyl; and each of m and n is an integer of 0-3 (m+n does not exceed 3); k is an integer of 1-4; each of p and i is an integer of 2-13; and each of q and j is an integer of 4-7.
摘要翻译:新型亚烷基二胺衍生物有效地可用的谷氨酸盐阻滞剂具有式(I)或(II):其中R 1和R 6各自为脂族烃基,脂环族烃基,芳基 ,或芳烷基; R 2和R 7各自为脂族烃基,烷氧基,含酯键的脂族烃基,含有醚键的脂族烃基或芳氧基; R 3,R 4,R 5,R 9和R 10各自为氢,烷基,烷氧基,酰氧基,芳基,芳烷基,羟基,羟基烷基,卤素,腈,硝基,氨基,氨基甲酰基 或烷氧基羰基; 并且m和n分别为0-3的整数(m + n不超过3); k是1-4的整数; p和i中的每一个是2-13的整数; 并且q和j中的每一个是4-7的整数。
摘要:
A therapeutic agent for liver disease containing as an active ingredient a piperazine derivative having the formula: ##STR1## wherein, A represents a phenyl, p-benzoquinonyl or cumarinyl group which may have at least one substituent selected from the group consisting of halogen, alkyl, fluoroalkyl, formyl, alkoxycarbonyl, acyl, hydroxy, alkoxy, acyloxy, glycosyloxy, amino, alkylamino, mercapto, alkylthio and nitro; B represents a single bond or a straight chain alkylene group containing 1-4 carbon atoms which may have at least one substituent selected from the group consisting of alkyl, aryl, aralkyl, hydroxy and oxo; R represents an atom or a group selected from the group consisting of hydrogen, alkali metal, alkaline earth metal, alkyl, cycloalkyl, aralkyl and aryl; and n is 2 or 3, or its pharmaceutically acceptable salt is disclosed.